Why the study?
Does the discontinuation of prasugrel lead to a gradual recovery of platelet function driven by juvenile platelets in patients with prior ST-elevation myocardial infarction?
Does the discontinuation of prasugrel lead to a gradual recovery of platelet function driven by juvenile platelets in patients with prior ST-elevation myocardial infarction?
The gradual recovery of platelet function after prasugrel discontinuation is driven by newly formed juvenile platelets, which exhibit increasing reactivity over time, providing mechanistic support for the guideline recommendation to stop prasugrel 7 days prior to surgery.
Answers are grounded in this paper and cite their sources.
Supports guideline 7-day prasugrel hold before surgery; leaves open effects on clinical outcomes.
In patients with acute coronary syndrome, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor like prasugrel is prescribed for one year. Here, we investigated how the hemostatic function of platelets recovers after discontinuation of prasugrel treatment. Therefore, 16 patients who suffered from ST-elevation myocardial infarction were investigated. Patients were treated with aspirin (100 mg/day, long-term) and stopped taking prasugrel (10 mg/day) after one year. Blood was collected at the last day of prasugrel intake and at 1, 2, 5, 12 and 30 days later. Platelet function in response to ADP was normalized between five and 30 days after treatment cessation and in vitro addition of the reversible P2Y12 receptor antagonist ticagrelor fully suppressed the regained activation response. Discontinuation of prasugrel resulted in the formation of an emerging subpopulation of ADP-responsive platelets, exhibiting high expression of active integrin αIIbβ3. Two different mRNA probes, thiazole orange and the novel 5'Cy5-oligo-dT probe revealed that this subpopulation consisted of juvenile platelets, which progressively contributed to platelet aggregation and thrombus formation under flow. During offset, juvenile platelets were overall more reactive than older platelets. Interestingly, the responsiveness of both juvenile and older platelets increased in time, pointing towards a residual inhibitory effect of prasugrel on the megakaryocyte level. In conclusion, the gradual increase in thrombogenicity after cessation of prasugrel treatment is due to the increased activity of juvenile platelets.
No takes yet. Share an insight, caveat, or question.
Baaten et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: